PharmaCyte Biotech, Inc.
PMCB
$1.64
-$0.12-6.82%
| Weiss Ratings | PMCB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C- | |||
| Rating Factors | PMCB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | PMCB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.81 | |||
| Price History | PMCB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.09% | |||
| 30-Day Total Return | 1.83% | |||
| 60-Day Total Return | -1.20% | |||
| 90-Day Total Return | -14.58% | |||
| Year to Date Total Return | -0.01% | |||
| 1-Year Total Return | -16.75% | |||
| 2-Year Total Return | -43.25% | |||
| 3-Year Total Return | -19.61% | |||
| 5-Year Total Return | -97.20% | |||
| 52-Week High % Change | -31.78% | |||
| 52-Week Low % Change | 26.62% | |||
| Price | PMCB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.58 | |||
| 52-Week Low Price | $1.39 | |||
| 52-Week Low Price (Date) | Aug 27, 2024 | |||
| 52-Week High Price (Date) | Mar 27, 2024 | |||
| Valuation | PMCB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 12.26M | |||
| Enterprise Value | -8.58M | |||
| Price/Earnings (TTM) | 2.11 | |||
| Earnings Per Share (TTM) | 0.83 | |||
| Earnings Per Share Growth | -198.80% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.28 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.64 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | 1.59 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | PMCB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 7.64M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | PMCB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 917-595-2850 | |||
| Address | 3960 Howard Hughes Parkway Las Vegas, NV 89169 | |||
| Website | pharmacyte.com | |||
| Country | United States | |||
| Year Founded | 1996 | |||
| Profitability | PMCB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | PMCB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -5.05% | |||
| Return on Equity | 43.18% | |||
| Income Statement | PMCB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -5.41M | |||
| Net Income (TTM) | 22.68M | |||
| Net Income Avl. to Common (TTM) | 22.68M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -152.68% | |||
| EPS Diluted (TTM) | 0.83 | |||
| EPS Diluted Growth (Q YOY) | -50.00% | |||
| Balance Sheet | PMCB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 20.84M | |||
| Cash Per Share (Q) | $2.73 | |||
| Total Current Assets (Q) | 21.33M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 43.45M | |||
| Current Ratio (Q) | 4.467 | |||
| Book Value Per Share (Q) | $6.18 | |||
| Total Assets (Q) | 55.10M | |||
| Total Current Liabilities (Q) | 4.78M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 11.65M | |||
| Total Common Equity (Q) | 43.45M | |||
| Cash Flow | PMCB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -12.00M | |||
| Cash from Financing (TTM) | -38.65M | |||
| Net Change in Cash (TTM) | -52.59M | |||
| Levered Free Cash Flow (TTM) | 522.60K | |||
| Cash from Operations (TTM) | -1.94M | |||
